
Translation





PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference							
PH-1955-PCT	FOR FURTHER AC	CTION	See Form PCT/IPEA/416				
International application No.	International filing dat	te (day/month/year)	Priority date (day/month/year)				
PCT/JP2003/015631	05 December 20		06 December 2002 (06.12.2002)				
International Patent Classification (IPC) or na			00 December 2002 (08.12.2002)				
C07D 265/36, 413/12, A61K 31/538, A61P 7/02, 9/00, 9/10							
Applicant	Applicant						
TORAY INDUSTRIES, INC.							
1. This report is the international prelim	ninary examination reno	art established by this	International Proliminary Provider				
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 							
2. This REPORT consists of a total of sheets, including this cover sheet.							
3. This report is also accompanied by ANNEXES, comprising:							
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:							
	a sheets, as follows:						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions)							
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.							
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))							
readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).							
4. This report contains indications relating to the following items:							
Box No. I Basis of the report							
Box No. II Priority							
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability							
Box No. IV Lack of unity of invention							
Box No. V Reasoned statement under Article 35(2) with regard to povelty, inventive etc.							
citations and explanations supporting such statement Box No. VI Certain documents cited							
Box No. VIII Certain observations on the international application							
— Second Coses various on the international application							
Date of submission of the demand		Date of completion of	this report				
01 March 2004 (01.03.2004)		11 Nove	ember 2004 (11.11.2004)				
Name and mailing address of the IPEA/JP		Authorized officer					
			· [
Facsimile No.		elephone No.	1				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Box N	lo. I	Basis of the report				
1. Wit oth	th regarderse i	rd to the language, this report is based on the international application in the lar indicated under this item.	nguage in which it was filed, unless			
	This whi	is report is based on translations from the original language into the followin ich is language of a translation furnished for the purpose of:	ng language,			
		international search (under Rules 12.3 and 23.1(b))				
		publication of the international application (under Rule 12.4)				
ĺ	international preliminary examination (under Rules 55.2 and/or 55.3)					
]		· · · · · · · · · · · · · · · · · · ·				
	dare not The in	rd to the elements of the international application, this report is based on to the receiving Office in response to an invitation under Article 14 are referred to this report): international application as originally filed/furnished description:	(replacement sheets which have been ed to in this report as "originally filed"			
╽┕	pages	•				
	pages		, as originally filed/furnished			
	pages	received by this Authority on				
		received by this Authority on				
	pages pages	o#	, as originally filed/furnished			
	pages'	, as amended (togo	gether with any statement) under Article 19			
ĺ	pages	received by this Authority on				
		received by this Authority on				
		rawings:				
	pages		, as originally filed/furnished			
	pages ⁴	received by this Authority on				
	_	leceived by this Authority off				
	a sequ	uence listing and/or any related table(s) – see Supplemental Box Relating to Sec	quence Listing.			
3.	The ar	mendments have resulted in the cancellation of:				
		the description, pages				
ĺ		the claims, Nos.				
ļ	=	the drawings, sheets/figs				
	Ħ	the sequence listing (energial).				
	H	the sequence listing (specify):				
	- لـــا	any table(s) related to sequence listing (specify):				
4.	(Rule 7	report has been established as if (some of) the amendments annexed to this resince they have been considered to go beyond the disclosure as filed, as in 70.2(c)).	port and listed below had not been indicated in the Supplemental Box			
		the claims, Nos.				
	□ •	the drawings, sheets/figs				
	<u> </u>	the sequence listing (specify):				
	Ī,	any table(s) related to sequence listing (specify):				
		as the sequence using (specify):				
* If iten	n 4 appl	lies, some or all of those sheets may be marked "superseded."				

	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Statement					
Novelty (N)	Claims	1-16	YES		
	Claims		МО		
Inventive step (IS)	Claims	1-16	YES		
	Claims		NO		
Industrial applicability (IA)	Claims	1-16	YES		
	Claims		NO.		

- 2. Citations and explanations (Rule 70.7)
- 1. EP, 1028113, A1 (Toray Industries, Inc.), 16 August, 2000
- 2. US, 2001/0003747, A1 (Adir et Compagnie), 14 June, 2001

Claims 1-16

The inventions described in claims 1-16 appear to be novel and to involve an inventive step over documents 1 and 2.

Document 1 describes a compound having platelet aggregation inhibitory action that is represented by General Formula (I). The aforementioned General Formula (I) includes the compound of this application; however, document 1 does not specifically describe a compound wherein A⁴ is -NR⁵CO-. Because the compound of this application has such a structure, it has particularly outstanding platelet aggregation inhibitory action as compared to the compound specifically described in document 1 (see example 3 of this application).

Document 2 describes benzomorpholine derivatives, which are identical in structure except for R⁴; however, it neither describes nor suggests introducing R⁴, nor does it describe platelet aggregation inhibitory action.

Furthermore, this examination finds that arriving at the compound of this application based on the inventions of documents 1 and 2 would not have been obvious to a party skilled in the art.